Joshua Grill, PhD, Director, Katherine and Benjamin Kagan Alzheimer’s Disease Treatment Development Program, UCLA, discusses biomarkers in Alzheimer’s Disease, which are currently used in clinical trials as inclusion criteria and outcome measures. The aim of using biomarkers is to halt disease development.

Reading:

Dean RA, Shaw LM.
Use of Cerebrospinal Fluid Biomarkers for Diagnosis of Incipient Alzheimer Disease in Patients with Mild Cognitive Impairment.
Clin Chem. 2009 Nov 19.

Mattsson N, Blennow K, Zetterberg H.
CSF biomarkers: pinpointing Alzheimer pathogenesis.
Ann N Y Acad Sci. 2009 Oct;1180:28-35.

Kester MI, van der Vlies AE, Blankenstein MA, Pijnenburg YA, van Elk EJ, Scheltens P, van der Flier WM.
CSF biomarkers predict rate of cognitive decline in Alzheimer disease.
Neurology. 2009 Oct 27;73(17):1353-8.